GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (OTCPK:MSCLF) » Definitions » Total Equity

MSCLF (Satellos Bioscience) Total Equity : $47.63 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Total Equity?

Satellos Bioscience's total equity for the quarter that ended in Dec. 2024 was $47.63 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Satellos Bioscience Total Equity Historical Data

The historical data trend for Satellos Bioscience's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Total Equity Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
-0.14 8.19 2.48 30.32 47.63

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.32 25.49 21.28 15.20 47.63

Satellos Bioscience Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Satellos Bioscience's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=51.251-3.618
=47.63

Satellos Bioscience's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=51.251-3.618
=47.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satellos Bioscience Total Equity Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (OTCPK:MSCLF) » Definitions » Total Equity
Comparable Companies
XCNQ:GLAB TSX:TH TSX:MDNA XCNQ:ONCO TSX:ONC TSXV:MIR TSXV:ARCH TSXV:COV TSX:MBX XCNQ:DTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0ITA:Germany MSCL:Canada
Address
200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.